Contribute Try STAT+ Today

When Laura Indolfi set out to launch a biotech in Boston, she had an idea — and little else. She had never run a company before. She had no practical experience in fundraising.

But she was undeterred. In 2014 she founded PanTher Therapeutics, with the goal of turning a postdoctoral side project into a bona-fide drug delivery company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I’m surprised that the writer didn’t mention that the Dyne CEOs kids play on the same teams with an Atlas partners – and that the Atlas partner holds ‘Wellesley Only’ biotech meetups once a month.

  • Social connections first, science second

    or, that’s why many biotech startups don’t go anywhere, and most are selling revolutionary hot air

Comments are closed.